Search

The Barcelona Science Park of the University of Barcelona (UB) will host two new research centres with ties to Barcelona’s Hospital Clínic: the August Pi i Sunyer Biomedical Research Institute

Oryzon Genomics, a clinical-stage biopharmaceutical company, is advancing vafidemstat, its LSD1 inhibitor for CNS disorders, as a potential treatment for Borderline Personality Disorder (BPD). BPD is

The newly created company, based in Santiago de Compostela, has been one of the three awardees in the IMPACTO 2024 edition.

BCN HEALTH, presents three different studies about the incidence and medical costs in prostate cancer, lupus and chronic obstructive respiratory disease. The study was made between June 2016 and

Zebrafish are valuable, robust, and cost-effective models for toxicity testing in the early stages of product development.

Conceived as a research-only tool, it helps healthcare professionals enhance their practice through genetics.

Company presented the data to the FDA and discussed potential registrational Phase III vafidemstat study for the treatment of BPD at a recent End-of-Phase II meeting.

Sector-specific regulations, such as the revision of European pharmaceutical legislation, the IVDR and MDR Regulations, and the Health Technology Assessment Regulation, significantly impact

Biotechnology is behind every medication being tested and eventually approved, making its contribution the key factor that has enabled improvements in treatments in recent years.

The eventoplus Awards are the top accolades for the events and meetings sector in Spain and Portugal, and the award ceremony took place on September 17.

ZETA, a leading provider of end-to-end solutions for the biopharma and pharma industry, has announced the acquisition of a majority stake in INOSIM Software GmbH, a German company that specializes in

Biorizon Biotech has become a global leader in agricultural biotechnology and is renowned for its innovative microalgae-based Trietech© technology. Since it was founded, the company has transformed

The factory, which has a production capacity of up to 10,000 tonnes per year, is equipped with state-of-the-art technology for processing omega-3 oil. The first oil production tests began in July and

Prominent researchers and health professionals shared success stories developed at the centre and discussed the future of fields such as personalised medicine, bioimaging, and robotic surgery.

Promega's contribution to the development and verification of genetically modified CAR-T cells is driving innovation in cancer immunotherapy.

AMSbiopharma’s Innovation Plan goes beyond improving internal processes, adopting a comprehensive approach that encompasses innovation in services, technology, and organization.

Proposals such as improving the financing environment for disruptive innovation, startups, and expanding companies, or maximizing the impact of the European Health Data Space, among others, are

It is estimated that in 2024, around 12,400 new cases of lymphoma will be diagnosed in Spain, the majority (approximately 85%) being non-Hodgkin.